[1]
|
Irving JA, Pike RN, Lesk AM, et al. Phylogeny of the Serpin Superfamily: Implications of Patterns of Amino Acid Conservation for Structure and Function[J]. Genome Res, 2000, 10: 1845-1864. doi: 10.1101/gr.147800 |
[2]
|
Kaiserman D, Bird PI. Control of Granzymes by Serpins[J]. Cell Death Differ, 2010, 17: 586-595. doi: 10.1038/cdd.2009.169 |
[3]
|
Silverman GA, Whisstock JC, Askew DJ, et al. Human Clade B Serpins (Ov-serpins) Belong to a Cohort of Evolutionarily Dispersed Intracellular Proteinase Inhibitor Clades That Protect Cells From Promiscuous Proteolysis[J]. Cell Mol Life Sci, 2004, 61: 301-325. doi: 10.1007/s00018-003-3240-3 |
[4]
|
Wang WJ, Wang J, Ouyang C, et al. Overview of serpin B9 and its roles in cancer (Review)[J]. Oncol Rep, 2021, 46: 190. doi: 10.3892/or.2021.8141 |
[5]
|
Medema JP, de Jong J, Peltenburg LT, et al. Blockade of the Granzyme B/Perforin Pathway Through Overexpression of the Serine Protease Inhibitor PI-9/SPI-6 Constitutes a Mechanism for Immune Escape by Tumors[J]. Proc Natl Acad Sci U S A, 2001, 98: 11515-11520. doi: 10.1073/pnas.201398198 |
[6]
|
Sun JR, Bird CH, Sutton V, et al. A Cytosolic Granzyme B Inhibitor Related to the Viral Apoptotic Regulator Cytokine Response Modifier A Is Present in Cytotoxic Lymphocytes[J]. J Biol Chem, 1996, 271: 27802-27809. doi: 10.1074/jbc.271.44.27802 |
[7]
|
Zhang ML, Park SM, Wang Y, et al. Serine Protease Inhibitor 6 Protects Cytotoxic T Cells From Self-inflicted Injury by Ensuring the Integrity of Cytotoxic Granules[J]. Immunity, 2006, 24: 451-461. doi: 10.1016/j.immuni.2006.02.002 |
[8]
|
Ansari AW, Temblay JN, Alyahya SH, et al. Serine Protease Inhibitor 6 Protects iNKT Cells From Self-inflicted Damage[J]. J Immunol, 2010, 185: 877-883. doi: 10.4049/jimmunol.1000651 |
[9]
|
Bird CH, Sutton VR, Sun J, et al. Selective Regulation of Apoptosis: the Cytotoxic Lymphocyte Serpin Proteinase Inhibitor 9 Protects Against Granzyme B-mediated Apoptosis Without Perturbing the Fas Cell Death Pathway[J]. Mol Cell Biol, 1998, 18: 6387-6398. doi: 10.1128/MCB.18.11.6387 |
[10]
|
Kummer JA, Micheau O, Schneider P, et al. Ectopic Expression of the Serine Protease Inhibitor PI9 Modulates Death Receptor-mediated Apoptosis[J]. Cell Death Differ, 2007, 14: 1486-1496. doi: 10.1038/sj.cdd.4402152 |
[11]
|
Cunningham TD, Jiang XG, Shapiro DJ. Expression of High Levels of Human Proteinase Inhibitor 9 Blocks Both Perforin/Granzyme and Fas/Fas Ligand-mediated Cytotoxi-city[J]. Cell Immunol, 2007, 245: 32-41. doi: 10.1016/j.cellimm.2007.03.004 |
[12]
|
Bladergroen BA, Strik MC, Bovenschen N, et al. The Granzyme B Inhibitor, Protease Inhibitor 9, Is Mainly Expressed by Dendritic Cells and at Immune-privileged Sites[J]. J Immunol, 2001, 166: 3218-3225. doi: 10.4049/jimmunol.166.5.3218 |
[13]
|
Azzi J, Skartsis N, Mounayar M, et al. Serine Protease Inhibitor 6 Plays a Critical Role in Protecting Murine Granzyme B-producing Regulatory T Cells[J]. J Immunol, 2013, 191: 2319-2327. doi: 10.4049/jimmunol.1300851 |
[14]
|
Bladergroen BA, Strik MCM, Wolbink AM, et al. The Granzyme B Inhibitor Proteinase Inhibitor 9 (PI9) Is Expressed by Human Mast Cells[J]. Eur J Immunol, 2005, 35: 1175-1183. doi: 10.1002/eji.200425949 |
[15]
|
Buzza MS, Hirst CE, Bird CH, et al. The Granzyme B Inhibitor, PI-9, Is Present in Endothelial and Mesothelial Cells, Suggesting That It Protects Bystander Cells During Immune Responses[J]. Cell Immunol, 2001, 210: 21-29. doi: 10.1006/cimm.2001.1806 |
[16]
|
Rizzitelli A, Meuter S, Vega Ramos J, et al. Serpinb9 (Spi6)-deficient Mice Are Impaired in Dendritic Cell-mediated Antigen Cross-presentation[J]. Immunol Cell Biol, 2012, 90: 841-851. doi: 10.1038/icb.2012.29 |
[17]
|
Garrido F. MHC/HLA Class I Loss in Cancer Cells[J]. Adv Exp Med Biol, 2019, 1151: 15-78. |
[18]
|
Rousalova I, Krepela E, Prochazka J, et al. Expression of Proteinase Inhibitor-9/serpinB9 in Non-small Cell Lung Carcinoma Cells and Tissues[J]. Int J Oncol, 2010, 36: 275-283. |
[19]
|
Soriano C, Mukaro V, Hodge G, et al. Increased Proteinase Inhibitor-9 (PI-9) and Reduced Granzyme B in Lung Cancer: Mechanism for Immune Evasion?[J]. Lung Cancer, 2012, 77: 38-45. doi: 10.1016/j.lungcan.2012.01.017 |
[20]
|
Zhou B, Chen EL, Chen JH, et al. Overexpression of Proteinase Inhibitor 9 Is Associated With Poor Prognosis in Human Hepatocellular Carcinoma and With Proliferation and Apoptosis in HepG2 Cells in vitro[J]. Int J Clin Exp Pathol, 2019, 12: 3719-3727. |
[21]
|
Vycital O, Pitule P, Hosek P, et al. Expression of Serpin B9 as a Prognostic Factor of Colorectal Cancer[J]. Anticancer Res, 2019, 39: 6063-6066. doi: 10.21873/anticanres.13813 |
[22]
|
Ray M, Hostetter DR, Loeb CRK, et al. Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis[J]. Prostate, 2012, 72: 846-855. doi: 10.1002/pros.21486 |
[23]
|
Fritsch K, Finke J, Grüllich C. Suppression of Granzyme B Activity and Caspase-3 Activation in Leukaemia Cells Constitutively Expressing the Protease Inhibitor 9[J]. Ann Hematol, 2013, 92: 1603-1609. doi: 10.1007/s00277-013-1846-6 |
[24]
|
Chen Y, Quan LN, Jia CM, et al. Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma[J]. J Proteome Res, 2021, 20: 2673-2686. doi: 10.1021/acs.jproteome.1c00007 |
[25]
|
van Houdt IS, Oudejans JJ, van den Eertwegh AJM, et al. Expression of the Apoptosis Inhibitor Protease Inhibitor 9 Predicts Clinical Outcome in Vaccinated Patients With Stage Ⅲ and Ⅳ Melanoma[J]. Clin Cancer Res, 2005, 11: 6400-6407. doi: 10.1158/1078-0432.CCR-05-0306 |
[26]
|
Van Allen EM, Miao DN, Schilling B, et al. Genomic Correlates of Response to CTLA-4 Blockade in Metastatic Melanoma[J]. Science, 2015, 350: 207-211. doi: 10.1126/science.aad0095 |
[27]
|
Jiang P, Gu SQ, Pan D, et al. Signatures of T cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response[J]. Nat Med, 2018, 24: 1550-1558. doi: 10.1038/s41591-018-0136-1 |
[28]
|
Jiang XJ, Wang J, Deng XY, et al. Role of the Tumor Microenvironment in PD-L1/PD-1-mediated Tumor Immune Escape[J]. Mol Cancer, 2019, 18: 10. doi: 10.1186/s12943-018-0928-4 |
[29]
|
Jiang LW, Wang YJ, Zhao J, et al. Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy[J]. Cell, 2020, 183: 1219-1233. e18. doi: 10.1016/j.cell.2020.10.045 |
[30]
|
Liu Y, Cao XT. Immunosuppressive Cells in Tumor Immune Escape and Metastasis[J]. J Mol Med (Berl), 2016, 94: 509-522. doi: 10.1007/s00109-015-1376-x |
[31]
|
Luo H, Ma C. Identification of Prognostic Genes in Uveal Melanoma Microenvironment[J]. PLoS One, 2020, 15: e0242263. doi: 10.1371/journal.pone.0242263 |
[32]
|
Peters FS, Peeters AMA, van den Bosch TPP, et al. Disrupted Regulation of serpinB9 in Circulating T Cells Is Associated With an Increased Risk for Post-transplant Skin Cancer[J]. Clin Exp Immunol, 2019, 197: 341-351. doi: 10.1111/cei.13309 |
[33]
|
Bladergroen BA, Meijer CJLM, ten Berge RL, et al. Expression of the Granzyme B Inhibitor, Protease Inhibitor 9, by Tumor Cells in Patients With non-Hodgkin and Hodgkin Lymphoma: a Novel Protective Mechanism for Tumor Cells to Circumvent the Immune System?[J]. Blood, 2002, 99: 232-237. doi: 10.1182/blood.V99.1.232 |
[34]
|
ten Berge RL, Meijer CJLM, Dukers DF, et al. Expression Levels of Apoptosis-related Proteins Predict Clinical Outcome in Anaplastic Large Cell Lymphoma[J]. Blood, 2002, 99: 4540-4546. doi: 10.1182/blood.V99.12.4540 |
[35]
|
Bossard C, Belhadj K, Reyes F, et al. Expression of the Granzyme B Inhibitor PI9 Predicts Outcome in Nasal NK/T-cell Lymphoma: Results of a Western Series of 48 Patients Treated With First-line Polychemotherapy Within the Grouped'Etude des Lymphomes de l'Adulte (GELA) Trials[J]. Blood, 2007, 109: 2183-2189. doi: 10.1182/blood-2006-07-033142 |